Literature DB >> 11862965

The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients.

O Löwhagen1, A M Wever, M Lusuardi, G Moscato, W A De Backer, L Gandola, C F Donner, S Ahlstedt, L Larsson, S T Holgate.   

Abstract

The objective of this study was to compare the inflammatory marker eosinophil cationic protein (ECP) with peak expiratory flow (PEF) in determining the therapeutic needs of inhaled corticosteroids in asthma patients assessed as asthma symptoms. A randomized, single-blind study over 6 months was performed at six specialist centres in Europe. In total, 164 adult patients with moderate to severe symptomatic asthma and regular use of inhaled corticosteroids were included. After a run-in period of 2 weeks patients were randomly allocated to the ECP or the PEF monitoring group. The dose of inhaled cort costeroids was adjusted every fourth week based on the current serum ECP value or pre-bronchodilator morning PEF values as surrogate markers of therapeutic needs. At the end of the study there were no statistically significant differences in the mean daily symptom score or the percentage of symptom-free days between the two groups. The mean daily dose of inhaled corticosteroids was similar in the two groups at the start of the study but the algorithms used to adjust the dose of inhaled corticosteroids resulted in an increased use of inhaled corticosteroids in both groups. The mean daily dose of inhaled corticosteroids over the whole study period was significantly lower in the ECP group compared withthe PEF group (1246 vs. 1667 microg, P = 0.026). In the ECP group, forced expiratory volume in I sec (FEV)% predicted was lower at the end ofthe study compared with the begining (92% vs. 87%, P = 0 .0009), although there was no significant difference between the two groups. None of the used algorithms for ECP and PEF led to improvement in symptom scores, in spite of increased doses of inhaled corticosteroids. In this respect, both methods were equivalent and insufficient. Recommendations suggesting lung function tests in current guidelines may be difficult to translate into clinical practice, however, a combination of inflammatory markers, lung function and symptoms may still improve asthma control.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11862965     DOI: 10.1053/rmed.2001.1218

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

Review 1.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 2.  Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

Review 3.  Personalised medicine and asthma diagnostics/management.

Authors:  Samuel J Wadsworth; Andrew J Sandford
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

4.  Serum eosinophil-derived neurotoxin (EDN) in diagnosis and evaluation of severity and bronchial hyperresponsiveness in childhood asthma.

Authors:  Kyung Won Kim; Kyung Eun Lee; Eun Soo Kim; Tae Won Song; Myung Hyun Sohn; Kyu-Earn Kim
Journal:  Lung       Date:  2007-03-28       Impact factor: 2.584

Review 5.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

6.  Clinical update on the use of biomarkers of airway inflammation in the management of asthma.

Authors:  Sj Wadsworth; Dd Sin; Dr Dorscheid
Journal:  J Asthma Allergy       Date:  2011-06-30

7.  Determinants Of Oral corticosteroid Responsiveness in Wheezing Asthmatic Youth (DOORWAY): protocol for a prospective multicentre cohort study of children with acute moderate-to-severe asthma exacerbations.

Authors:  F M Ducharme; R Zemek; J Gravel; D Chalut; N Poonai; S Laberge; C Quach; M Krajinovic; C Guimont; C Lemière; M C Guertin
Journal:  BMJ Open       Date:  2014-04-07       Impact factor: 2.692

8.  Serial Changes in Serum Eosinophil-associated Mediators between Atopic and Non-atopic Children after Mycoplasma pneumoniae pneumonia.

Authors:  Joo-Hwa Kim; Tae-Shik Cho; Jin-Hwa Moon; Chang-Ryul Kim; Jae-Won Oh
Journal:  Allergy Asthma Immunol Res       Date:  2014-06-04       Impact factor: 5.764

Review 9.  Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases.

Authors:  Dean D Metcalfe; Ruby Pawankar; Steven J Ackerman; Cem Akin; Frederic Clayton; Franco H Falcone; Gerald J Gleich; Anne-Marie Irani; Mats W Johansson; Amy D Klion; Kristin M Leiferman; Francesca Levi-Schaffer; Gunnar Nilsson; Yoshimichi Okayama; Calman Prussin; John T Schroeder; Lawrence B Schwartz; Hans-Uwe Simon; Andrew F Walls; Massimo Triggiani
Journal:  World Allergy Organ J       Date:  2016-02-11       Impact factor: 4.084

10.  Eosinophil Cationic Protein Concentrations among Crop and Dairy Farmers with Asthma.

Authors:  Saso Stoleski; Jordan Minov; Jovanka Karadzinska-Bislimovska; Dragan Mijakoski; Aneta Atanasovska
Journal:  Open Access Maced J Med Sci       Date:  2018-02-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.